Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘organoids’

Cancer’s Tiny Doppelgangers

Letting the genie out in San Diego

In our penultimate preview of the AACR24 meeting in San Diego – there’s one more to come folks – we take a look at another emerging trend at the meeting, which has impact for those involved drug discovery.

AACR is very much a window into the future of cancer research.

Thanks to the power of AI/ML computing technologies, what was once an obscure research tool is now starting to impact drug development as commercial companies begin to use it for the identification of novel targets.

In this post, we’ve not only highlighted abstracts and sessions of interest around this emerging area, but also compare, contrast, discuss the opportunities and limitations, then explain why this is something you should definitely be watching out for if you are involved in oncology new product development.

Stay tuned for our final AACR24 Preview coming later this week!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

5 important topics to watch out for at AACR22 on bispecifics

In the first part of our bispecific antibody review from the AACR front (the second will post next week), we highlight some strategic issues of interest to the field through the lens of several company’s data being presented at the meeting.

When we look at the themes of the meeting (right) we learn about the focus for this year’s event:

  • Decoding cancer complexity
  • Integrating science
  • Transforming patient outcomes

These are all particularly relevant to the the bispecific niche because whilst there are many of them, not all will make it to the finish line if they fail to improve outcomes and some will be consigned to the dreaded dog drug heaven status.

Think about it – you can have the grooviest bispecific molecule design ever, but if people taking it don’t live longer then it will likely get canned down the road in order to make way for a new era of novel targets and agents.

It’s time for some weekend reading – in the first part of our look at the bispecific antibody space, we highlight five key elements (with examples) to watch out for…

BSB subscribers can read our latest conference coverage and commentary – you can either log-in or click to access.

This content is restricted to subscribers

Defense is the Best Attack – Part 1

Gaudi’s Casa Milà/La Pedrera, Barcelona

Barcelona: There’s a lot of choice when it comes to cancer immunotherapy conferences, but an event that caught our attention this year as one that merited coverage is the European Association for Cancer Research (EACR) meeting, Defense is the Best Attack – Immuno-Oncology Breakthroughs taking place in Barcelona this week.

The conference is being held in the basement of La Pedrera, Gaudi’s famous Casa Milà modernist building in Barcelona (right).

It’s such an old building that you’re actually forbidden to plug in any phones or computers to charge them for fear of over-loading the electrics, so it’s an event that requires you to be fully charged upfront!

What were some of the highlights from Day 1?  There were some key data and concepts being presented that will grab folks involved in cancer research…

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!